Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
125.4 USD | +0.25% | -1.09% | +15.00% |
Apr. 15 | Zacks Adjusts Price Target on Merck & Company to $132 From $128 | MT |
Apr. 11 | Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.00% | 318B | B- | ||
+28.79% | 676B | C+ | ||
+24.77% | 554B | B | ||
-7.64% | 349B | C+ | ||
+5.99% | 291B | C+ | ||
+3.72% | 210B | B+ | ||
-0.28% | 204B | B- | ||
-9.65% | 194B | A+ | ||
-11.71% | 144B | C+ | ||
-8.32% | 142B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck & Co., Inc.